Non-small cell lung cancer · 5 regimens
Cost vs Efficacy · 3 points
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Cabozantinib monotherapy Variant #01 | — | R 90 983 | 28d | 4.3 mo | — | 5 | R 454 914 PFS proxy | 1 |
Cabozantinib and Erlotinib Variant #01 | — | R 74 562 | 28d | 4.7 mo | — | 6 | R 447 373 PFS proxy | 1 |
Docetaxel monotherapy N/A - secondary systemic drug | — | R 243 | 28d | 3.2 mo | 9.8 mo | 4 | R 973 PFS proxy | 39 |
Placebo Partial | — | — | — | — | 6.3 mo | — | — | 5 |
Anlotinib monotherapy Variant #01 Partial | — | — | 21d | — | 9.6 mo | — | — | 1 |
5 of 5 regimens shown